Charles River Laboratories
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells roden… Read more
Charles River Laboratories (CRL) - Total Assets
Latest total assets as of September 2025: $7.51 Billion USD
Based on the latest financial reports, Charles River Laboratories (CRL) holds total assets worth $7.51 Billion USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Charles River Laboratories - Total Assets Trend (1998–2024)
This chart illustrates how Charles River Laboratories’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Charles River Laboratories - Asset Composition Analysis
Current Asset Composition (December 2024)
Charles River Laboratories's total assets of $7.51 Billion consist of 18.6% current assets and 81.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $194.61 Million | 2.6% |
| Accounts Receivable | $720.91 Million | 9.6% |
| Inventory | $278.54 Million | 3.7% |
| Property, Plant & Equipment | $2.02 Billion | 26.8% |
| Intangible Assets | $723.40 Million | 9.6% |
| Goodwill | $2.85 Billion | 37.8% |
Asset Composition Trend (1998–2024)
This chart illustrates how Charles River Laboratories's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Charles River Laboratories's current assets represent 18.6% of total assets in 2024, a decrease from 41.5% in 1998.
- Cash Position: Cash and equivalents constituted 2.6% of total assets in 2024, down from 10.6% in 1998.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 46.0% of total assets, an increase from 14.0% in 1998.
- Asset Diversification: The largest asset category is goodwill at 37.8% of total assets.
Charles River Laboratories Competitors by Total Assets
Key competitors of Charles River Laboratories based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF
|
USA | $4.51 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
NSN Co. Ltd
KQ:031860
|
Korea | ₩60.96 Billion |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
Charles River Laboratories - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Charles River Laboratories generates 0.54x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Charles River Laboratories generates $ 0.14 in net profit.
Charles River Laboratories - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.37 | 1.48 | 1.43 |
| Quick Ratio | 1.10 | 1.14 | 1.21 |
| Cash Ratio | 0.18 | 0.21 | 0.00 |
| Working Capital | $410.22 Million | $ 482.50 Million | $ 361.38 Million |
Charles River Laboratories - Advanced Valuation Insights
This section examines the relationship between Charles River Laboratories's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.29 |
| Latest Market Cap to Assets Ratio | 0.99 |
| Asset Growth Rate (YoY) | -8.1% |
| Total Assets | $7.53 Billion |
| Market Capitalization | $7.48 Billion USD |
Valuation Analysis
Near Book Valuation: The market values Charles River Laboratories's assets close to their book value ( 0.99x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Charles River Laboratories's assets decreased by 8.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Charles River Laboratories (1998–2024)
The table below shows the annual total assets of Charles River Laboratories from 1998 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $7.53 Billion | -8.13% |
| 2023-12-31 | $8.20 Billion | +7.79% |
| 2022-12-31 | $7.60 Billion | +8.24% |
| 2021-12-31 | $7.02 Billion | +27.93% |
| 2020-12-31 | $5.49 Billion | +17.01% |
| 2019-12-31 | $4.69 Billion | +21.70% |
| 2018-12-31 | $3.86 Billion | +31.60% |
| 2017-12-31 | $2.93 Billion | +8.04% |
| 2016-12-31 | $2.71 Billion | +31.10% |
| 2015-12-31 | $2.07 Billion | +9.72% |
| 2014-12-31 | $1.89 Billion | +14.63% |
| 2013-12-31 | $1.64 Billion | +3.67% |
| 2012-12-31 | $1.59 Billion | +1.80% |
| 2011-12-31 | $1.56 Billion | -10.10% |
| 2010-12-31 | $1.73 Billion | -21.36% |
| 2009-12-31 | $2.20 Billion | +2.05% |
| 2008-12-31 | $2.16 Billion | -23.01% |
| 2007-12-31 | $2.81 Billion | +9.70% |
| 2006-12-31 | $2.56 Billion | +0.76% |
| 2005-12-31 | $2.54 Billion | -3.37% |
| 2004-12-31 | $2.63 Billion | +228.54% |
| 2003-12-31 | $799.55 Million | +14.00% |
| 2002-12-31 | $701.34 Million | +22.75% |
| 2001-12-31 | $571.36 Million | +39.15% |
| 2000-12-31 | $410.61 Million | +13.10% |
| 1999-12-31 | $363.06 Million | +54.98% |
| 1998-12-31 | $234.25 Million | -- |